AXIS Capital Holdings Limited reported 15% year-over-year growth in premiums written and diluted book value, maintaining a strong combined ratio of 93.1%. Despite a 25% decline in reinsurance premiums, its Series E preferred stock (AXS.PR.E) provides fixed-rate, non-cumulative dividends eligible for qualified dividend income (QDI) and holds a BBB credit rating. This preferred stock appeals to income-focused investors seeking stability, with a portfolio strategy emphasizing fixed coupons, call protection, and tax efficiency. The stock is rated a Buy for its yield, coverage ratios, and diversification benefits, even with a low chance of being called soon.
NRx Pharmaceuticals is set to report quarterly earnings with an expected loss of $0.09 per share and revenue of $1.33 million, reflecting ongoing financial challenges. Despite negative profitability and cash flow metrics, the company received positiv...
Applied Materials reported strong Q3 financial results with revenue up 25% to $9.12 billion and adjusted EPS rising 41% to $3.50, beating Wall Street estimates. However, the stock fell over 5% after earnings due to market expectations being even high...
Ascendis Pharma reported robust Q2 2026 results with total revenue of €339 million, driven by strong sales of its three main products: YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company achieved a net profit of €207 million and ended the quarter with a...
Matador Resources reported a record oil production of 126,106 barrels per day in Q2 2026, driving a 70.6% rise in adjusted earnings per share to $2.61 and a 32.5% increase in revenues to $1.2 billion. The CEO's recent purchase of 5,000 shares at $51....
Star Equity Holdings reported Q2 2026 results missing analyst expectations with an EPS of -$0.15 versus -$0.07 expected and revenue of $54.9 million below the $56.92 million forecast. Despite the miss, revenue grew 54.6% year-over-year, showing stron...
